Lysosomal Therapeutics raises $20M Series A from Sanofi, Lilly and Roche for Parkinson’s drug
Cambridge biotech Lysosomal Therapeutics just raised a whopping $20 million Series A for its small molecule Parkinson’s disease treatment, with backing from the venture arms of several big pharma – Sanofi, Lilly and Roche. The company will use the proceeds of this round to optimize its main compound, and preclinically develop a glucocerebrosidase lysosomal enzyme […]